Sat Kartar Shopping LtdQ3 FY25Pharmaceuticals & Biotechnology

Sat Kartar Shopping Ltd

Q3 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 1

→Sat Kartar aims to reach INR 200+ crores revenue in 2026 and INR 300 crores by FY 2027.
→The company targets INR 500 crores revenue by FY 2028, focusing mainly on Ayurveda products.
→Hospital segment (300 beds) expected to be operational by Q4 FY '27 but not included in revenue projections so far.
→Manufacturing capacity built for capsule and powder products; aiming to self-manufacture about 50% of capsules by Q1 next year.
→Growth driven by increased repeat rates (now calculated across product range per customer, currently at 25%) and average ticket size rise (~5% increase to ~INR 3,300).
→AI-driven analytics and digital initiatives to boost customer acquisition and optimize sales.
→Capacity utilization of new manufacturing started at 10%, expected to ramp up gradually.
→EBITDA margin target: 15% by FY '27 and up to 18%-20% in near future.
→Margins expected to improve with operating leverage, cost efficiencies, and repeat customer growth.

Margin guidance

Category 1

→PAT margin expected to grow from 6% in the past to 9-10% in the current year, targeting 12-15% by FY '27 and aiming for 18-20% EBITDA margin in the near future.
→Revenue target of INR 300 crores by FY '27 with 25%-30% EBITDA margins in hospitals segment.
→Capacity utilization and operational efficiencies projected to drive margin improvements.
→AI-driven data analytics expected to enhance sales efficiency and contribute to profitability.
→Advertising costs expected to remain stable or decrease by 100-200 basis points, with cost pressures mitigated by operational efficiency.
→Manufacturing capacity will support 50% in-house production, balancing asset-light model and business continuity.
→Long-term vision includes revenue of INR 500 crores by FY '28, focusing on Ayurveda products and complementary hospitals revenue.
→Repeat customer rate increasing and average ticket size rising (~5%), supporting steady earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

- Currently, Sat Kartar Shopping Limited has no plans to raise equity through preferential allotment or any other mode. - The company intends to fund its future growth, including hospital expansion, primarily through internal accruals. - Manprit Singh Chadha mentioned being not in a mood to increase equity at this stage but did hint at the possibility of a bonus issue if things go as planned. - There was no specific mention of raising debt for funding in the provided transcript. - The company prefers an asset-light model and has invested minimally in a factory to maintain flexibility. In summary, the company aims to grow using internal funds without immediate plans for new equity or debt fundraising.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Sat Kartar Shopping Limited.
→Discussions primarily focus on revenue targets (INR 300 crores by FY '27, INR 500 crores by FY '28) and segment contributions.
→The company expects growth driven by the Ayurveda product segment, with hospitals potentially complementing but not guaranteed revenue.
→There is mention of increased customer acquisition costs and competitive pressures but no direct reference to order backlog.
→Operational updates include hospital bed capacities becoming functional by FY '27 and capsule manufacturing ramp-up to 50% by Q1 FY '27.
→Overall, forward-looking plans emphasize revenue growth through internal operational scaling and increased product penetration rather than specific pending orders or order books.

Capex plans

Yes

→Sat Kartar has opened a manufacturing factory with minimal capex (less than INR 1 crore), focusing on producing up to 50% of capsule intake (about 25% of total intake) to maintain supply chain flexibility and serve as an R&D lab.
→Planning to start manufacturing 50% of capsules by Q1 FY 2026.
→Setting up a 300-bed Ayurveda hospital expected to be operational by Q4 FY 2027, starting with 30 beds in Q1 FY 2027 near NCR region.
→No immediate plan for equity raise; future funding for hospitals and growth expected through internal accruals.
→AI-driven initiatives are being launched to enhance data utilization and sales efficiency.
→Capex payback for manufacturing estimated around 18 months.
→Contract manufacturing model will continue alongside in-house manufacturing for safety and flexibility.

How does Sat Kartar Shopping Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sat Kartar Shopping Ltd

Rev 1Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Unlock with Pro

Want more stocks like Sat Kartar Shopping Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio